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Abstract
Background: Many factors influence bone metastases of lung cancer, and several studies report about survival of
skeletal metastasis. However, few studies have focused on identifying the prognostic factors for skeletal metastasis
of lung cancer, especially following orthopedic surgery. We conducted a retrospective analysis of the clinical
characteristics of skeletal metastasis from lung cancer and discuss the prognostic factors.
Methods: We performed a medical record review of 202 patients who were diagnosed with skeletal metastasis
from lung cancer. Adenocarcinoma was found in 116 patients (57.4%), squamous cell carcinoma in 29 (14.4%),
small-cell lung cancer (SCLC) in 37 (18.7%), and large-cell carcinoma and other types of cancer in 20 patients (9.9%).
Orthopedic surgery for skeletal metastasis was performed in 41 patients (20.3%).
Results: Lung cancer survival was 12.1 months. After diagnosis of lung cancer, skeletal metastasis was found at a
mean of 2.5 months, and skeletal metastasis survival was 9.8 months. Lung cancer survival in patients younger than
60 years was 13.8 months, and lung cancer survival in patients 60 years or older was 10.8 months (p = 0.009). Skeletal
metastasis survival in patients younger than 60 years was 11.0 months, and skeletal metastasis survival in patients
60 years or older was 8.8 months (p = 0.002). Mean skeletal metastasis survival with surgery was 12.6 months and
without surgery was 9.1 months (p < 0.000). In the multivariate analysis of lung cancer survival, age under 60 years
[HR (95% CI) 1.549 (1.122–2.139), p = 0.008], non-small cell lung cancer pathology type [HR (95% CI) 1.711 (1.157–2.
532), p = 0.008], chemotherapy for skeletal metastasis [HR (95% CI) 8.064 (3.981–16.332), p < 0.000], and radiation
therapy for skeletal metastasis [HR (95% CI) 1.791 (1.170–2.742), p = 0.007] were significant, independent, good
prognostic factors. In the multivariate analysis of skeletal metastasis survival, age under 60 years [HR (95% CI) 1.549
(1.124–2.134), p = 0.007], non-small cell lung cancer pathology type [HR (95% CI) 2.045 (1.373–3.047), p < 0.000],
chemotherapy for skeletal metastasis [HR (95% CI) 7.121 (3.542–14.317), p < 0.000], and orthopedic surgical
treatment for skeletal metastasis [HR (95% CI) 1.710 (1.148–2.547), p = 0.008] were significant, independent, good
prognostic factors.
Conclusions: Patients who survived longer were less than 60 years old, received chemotherapy as treatment for
skeletal metastasis, had NSCLC rather than SCLC, and underwent orthopedic surgery for skeletal metastasis.
Keywords: Lung neoplasms, Multivariate analysis, Bone neoplasms
Background
Lung cancer is the leading cause of cancer-related deaths
worldwide, accounting for almost 20% of cancer-related
fatalities [1, 2]. The incidence of lung cancer is about
53.6/100,000 people every year, and mortality is 45.6/
100,000 every year [3]. The skeletal system is one of the
most common distal metastatic sites in patients with
lung cancer, and 30–40% of those with advanced lung
cancer develop skeletal metastases [4, 5]. Skeletal metas-
tasis involves significant morbidity, metabolic disorders
such as hypercalcemia, pathologic fractures, and spinal
cord compression. These disease sequelae entail a reduc-
tion in quality of life and require costly treatments that
have limited impact on overall survival. The importance
of metastasis from lung cancer has been overlooked in
patients with advanced lung cancer because the mean
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survival is less than 6 months [6]. The recent develop-
ment of remarkable chemotherapy and supportive ther-
apies has caused the average survival time in patients
with lung cancer to dramatically increase, and interest in
skeletal metastasis of lung cancer has increased. Patho-
logic fractures, or skeletal-related events (SREs), follow-
ing the skeletal metastasis of lung cancer can
substantially reduce quality of life and increase economic
burden. Some reports have stated that the incidence of
SREs are reduced with use of medications, such as
bisphosphonates and denosumab, for lung cancer that has
metastasized to the limbs of the skeletal system [7–10].
Traditionally, orthopedic surgery, such as open reduction
internal fixation, has been an important treatment
method. Many factors influence bone metastases of lung
cancer, including age, sex, pathologic type, number of pri-
mary lesions, number of bone metastases, treatment regi-
mens, and serum markers [11]. However, few studies have
focused on identifying the prognostic factors for skeletal
metastasis from lung cancer, especially following ortho-
pedic surgery. Therefore, we conducted a retrospective
analysis of the clinical characteristics of skeletal metastasis
from lung cancer and discuss the prognostic factors.
Methods
Participants
From January 1, 2005 to December 31, 2015, a total 329
patients with lung cancer who were diagnosed with
skeletal metastatic disease were recruited from three in-
stitutions. For the purpose of analysis, the following ex-
clusion criteria were applied: 1) patients who had only
spinal metastasis without appendix bone metastasis (n =
82) and 2) patients who had undergone an operation on
the small bones of the hands or feet (n = 3). Of the
remaining 244 patients, 42 patients with less than 24
months of follow up were excluded, which left us with
202 patients for medical record review.
Of the total 202 patients, 126 (62.4%) were male and
76 (37.6%) were female. The mean age was 61.2 years
(range: 29–85 years). Adenocarcinoma was found in 116
patients (57.4%), squamous cell carcinoma in 29 (14.4%),
small-cell lung cancer (SCLC) in 37 (18.7%), and
large-cell carcinoma and other types of cancer in 20 pa-
tients (9.9%). A total 114 patients (56.4%) had a history
of smoking at the time of diagnosis, and 88 (43.6%) had
no smoking history. Hypertension was diagnosed in 50
cases (24.8%), and diabetic mellitus was 26 cases
(12.9%), chronic renal failure was 3 cases (1.5%). Chemo-
therapy was administered in 192 cases (95.0%) for
skeletal metastasis from lung cancer, and radiation
therapy was used in 174 cases (86.1%) (Table 1). We
reviewed plain radiography, magnetic resonance imaging
(MRI), computed tomography (CT), whole body bone
scan (WBBS), and positron emission tomography–
computed tomography (PET-CT). When the patient’s
imaging results showed two or more positive findings,
the patient was confirmed to have skeletal metastases. In
41 patients who underwent orthopedic surgery, patho-
logic examination of the metastatic site was performed.
In all cases, metastatic lung cancer was reported. A typ-
ical example from diagnosis to progression, operation
and the results was shown in Fig. 1. The patients were
followed for 24 months in an open patients department
visit and/or telephone interview. We analyzed the sur-
vival rate and prognostic factors of patients with lung
cancer who had skeletal metastases (Table 1). Ethics ap-
proval was obtained from the Ethics Committee from all
three participating hospitals.
Statistical analysis
The general characteristics and basic data of patients were
summarized using descriptive statistics. The correlation
between survival length after diagnosis of lung cancer,
diagnosis of skeletal metastasis, and clinicopathologic vari-
ables was analyzed using an independent sample t-test.
For survival analysis, lung cancer survival was defined as
the time interval between the diagnosis of lung cancer and
death or the last follow-up. Skeletal metastasis survival
was defined as the time interval between the diagnosis of
skeletal metastasis from lung cancer and death or the last
follow-up. Lung cancer survival analyses and skeletal me-
tastasis survival analyses were conducted according to the
Kaplan-Meier method. Univariate and multivariate ana-
lyses were done using a proportional hazard regression
model (cut-off p value of 0.05). A multivariate analysis in-
cluded significant and non-redundant variables selected
from the univariate analysis [12]. All statistical analyses
were carried out using IBM SPSS version 18.0 (SPSS Inc.,
Chicago, Illinois, USA). Results were considered statisti-
cally significant if p < 0.05.
Results
Demographic data
A total of 128 patients (63.4%) were found to have
multiple distant metastases, including skeletal metas-
tases, at the time of lung cancer diagnosis, and 35
patients (17.3%) only had skeletal metastases at the
time of lung cancer diagnosis. Epidermal growth fac-
tor receptor (EGFR) mutation was detected in 18 pa-
tients (8.9%) and not detected in 53 patients (26.2%);
EGFR mutation tests were not performed in the
remaining 131 patients (64.9%). There were 43 pa-
tients (21.3%) with one other distant organ metasta-
sis, 78 (38.6%) with two, 52 (25.7%) with three, 22
(10.9%) with four, and six patients (3.0%) with five
other distant organ metastases. One patient (0.5%)
had more than six other distant organ metastases at
the time of diagnosis of skeletal metastasis. Distant
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organ metastases included 20 cases involving the
mediastinum, 69 of the liver, 177 involving the
lymph nodes, 29 of the chest wall, 101 of the cranial
cavity, 55 of the adrenal glands, and 28 cases involv-
ing the kidneys.
Lung cancer survival was 12.1 months (range: 1–44
months). After diagnosis of lung cancer, skeletal metas-
tasis was found at a mean of 2.5 months (range: 0–27
months); other organ metastases were found at a mean
of 2.9 months (range: 0–24months) after diagnosis of
lung cancer. Orthopedic surgical treatment was
performed in 41 patients (20.3%). At the last follow-up,
166 patients (82.20%) had died; skeletal metastasis sur-
vival was 9.8 months (range: 1–24 months).
Among patients diagnosed with skeletal metastasis,
patients younger than 60 years survived an average of
13.8 months, and those aged 60 years or older survived
an average of 10.8 months after diagnosis of lung cancer
(p = 0.009). After diagnosis of skeletal metastasis, pa-
tients younger than 60 years survived an average of 11.0
months, and those aged 60 years or older survived an
average of 8.8 months (p = 0.002).
Table 1 Demographic data of patients with skeletal metastasis from lung cancer
Lung cancer survival Skeletal metastasis survival
Patients, n (%) Survival (months) p-value Survival (months) p-value
Age, years
< 60 88 (43.6%) 13.8 0.009 11.0 0.002
≥ 60 114 (56.4%) 10.8 8.8
Sex
Male 126 (62.4%) 12.2 0.850 9.5 0.327
Female 76 (37.6%) 11.9 10.2
Pathology
Adenocarcinoma 116 (57.4%) NSCLC 12.6 0.080 10.4 0.000
Squamous cell carcinoma 29 (14.4%)
Large cell and other type lung cancer 20 (9.9%)
Small cell lung cancer 37 (18.3%) SCLC 10.0 7.2
Smoking
Smoker 114 (56.4%) 12.0 0.968 9.4 0.216
Non-smoker 88 (43.6%) 12.1 10.3
Hypertension
No 152 (75.2%) 11.9 0.545 9.6 0.421
Yes 50 (24.8%) 12.7 10.2
Diabetic Mellitus
No 176 (87.1%) 11.9 0.400 9.6 0.332
Yes 26 (12.9%) 13.3 10.6
Chronic renal failure
No 199 (98.5%) 12.1 0.960 9.7 0.370
Yes 3 (1.5%) 12.3 12.3
Chemotherapy
Do 192 (95%) 12.6 0.000 10.1 0.000
Undo 10 (5%) 3.2 3.2
Radiation therapy
Do 174 (86.1%) 12.5 0.062 9.9 0.147
Undo 28 (13.9%) 9.5 8.5
Orthopedic surgery
Do 41 (20.3%) 14.1 0.079 12.6 0.000
Undo 161 (79.7%) 11.6 9.1
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After the diagnosis of lung cancer, the average sur-
vival rate was 12.2 months in male patients and 11.9
months in female patients (p = 0.850). Males survived
an average of 9.5 months and females survived an
average of 10.2 months after skeletal metastasis diag-
nosis (p = 0.327). After a diagnosis of lung cancer, the
114 patients with a smoking history (56.4%) survived
an average of 12.0 months, and the 88 patients with
no smoking history survived an average of 12.1
months (p = 0.968). Patients with non-small cell lung
cancer (NSCLC) survived an average of 12.6 months
after diagnosis of lung cancer, and those with
small-cell carcinoma survived an average of 10.0
months (p = 0.080). Patients with NSCLC survived an
average of 10.4 months after diagnosis of skeletal me-
tastasis, and those with small-cell carcinoma survived
an average of 7.2 months (p = 0.000). We could not
find any statistical significances in lung cancer sur-
vival and skeletal metastasis survival in patients with
and without hypertension, diabetic mellitus, chronic
renal failure (Table 1).
One hundred ninety-two patients (95%) underwent
chemotherapy for skeletal metastasis, and their lung can-
cer survival was 12.6months. Lung cancer survival in 10
patients (5%) without chemotherapy was 3.2months (p <
0.000). The skeletal metastasis survival of patients who
underwent chemotherapy for skeletal metastasis was 10.1
months, and the skeletal metastasis survival of patients
who were not treated with chemotherapy was 3.2months
(p < 0.000). One hundred seventy-four patients (86.1%)
underwent radiation therapy for skeletal metastasis, and
their lung cancer survival was 12.5months. Lung cancer
survival in 28 patients (13.9%) without radiation therapy
was 9.5months (p = 0.062). The skeletal metastasis sur-
vival of patients who underwent radiation therapy for skel-
etal metastasis was 9.9months, and the skeletal metastasis
survival of patients who were not treated with radiation
was 8.5months (p = 0.147).
Forty-one patients (20.3%) underwent orthopedic sur-
gery for pathologic fractures or impending fractures sec-
ondary to the underlying skeletal metastasis from lung
cancer. The average age of patients with a diagnosis of
Fig. 1 A 66-year-old man who visited our hospital for hemoptysis. a Chest X-ray showed right costo-phrenic angle blurring. b Chest CT scan
showed a 4 cm-sized mass. Squamous cell carcinoma was diagnosed by bronchoscopic biopsy. c At the time of diagnosis, the stage was T3N2M0. d At
follow-up, WBBS was performed at 20 months of diagnosis, and hot-uptake was observed at the 2nd Lumbar body, left distal femur diaphysis and right
distal tibia diaphysis. e The osteolytic lesions are observed in the lateral cortex of the left femur diaphysis and lateral cortex of right tibia
diaphysis, suggesting skeletal metastases. f In chest X-ray, the haziness was increased at the right mid and lower lung field. g Curettage,
flexible intramedullary nailing, plate fixation and bone cementing were performed on the right distal tibia diaphysis metastasis.
Interlocking intramedullary nailing was performed on the left femur distal diaphysis metastasis. Additional postoperative radiation therapy
was performed, and chemotherapy was continued. h Ten months after surgery, there was a slight increase in the size of the osteolytic
lesions around the surgical sites, but full weight bearing without pain was possible. i The patient expired from pneumonia associated
with lung cancer
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lung cancer who underwent orthopedic surgery was
59.7 years; the average age of patients who did not have
surgery was 61.4 years (p = 0.374). Mean lung cancer sur-
vival of patients who underwent orthopedic surgery was
14.1 months, and mean lung cancer survival was 11.6
months in patients without surgery (p = 0.079). Mean
skeletal metastasis survival in patients who underwent
surgery was 12.6 months; without surgery, mean survival
after diagnosis of skeletal metastasis was 9.1 months (p
< 0.000) (Table 1).
Univariate and multivariate regression analysis of lung
cancer survival
Lung cancer diagnosed under 60 years of age [HR
(95% CI) 1.538 (1.159–2.161), p = 0.002], small cell
lung cancer pathology type [HR (95% CI) 1.630
(1.114–2.385), p = 0.008], chemotherapy for skeletal
metastasis [HR (95% CI) 9.827 (4.939–19.552), p <
0.000], and radiation therapy for skeletal metastasis
[HR (95% CI) 1.597 (1.048–2.434), p = 0.021] were
significantly associated with longer lung cancer sur-
vival (Fig. 2). In addition, the multivariate analysis
performed to determine which factors were an inde-
pendent prognostic factor revealed that age under 60
years at diagnosis [HR (95% CI) 1.549 (1.122–2.139),
p = 0.008], small cell lung cancer pathology type [HR
(95% CI) 1.711 (1.157–2.532), p = 0.007], chemother-
apy for skeletal metastasis [HR (95% CI) 8.064
(3.981–16.332), p < 0.000], and radiation therapy for
skeletal metastasis [HR (95% CI) 1.791 (1.170–2.742),
p = 0.007] were significant independent prognostic
factors (Table 2).
Univariate and multivariate regression analysis of skeletal
metastasis survival
The following factors were significantly associated with
longer skeletal metastasis survival: lung cancer diag-
nosed under 60 years of age [HR (95% CI) 1.619 (1.183–
2.216), p = 0.002], small cell lung cancer pathology type
[HR (95% CI) 1.950 (1.309–2.904), p < 0.000],
Fig. 2 Kaplan-Meier plots of lung cancer survival according to a) age at diagnosis of lung cancer, b) pathologic type of lung cancer, c) whether
chemotherapy was performed for skeletal metastasis, and d) whether radiation therapy was performed for skeletal metastasis. Median survivals
are expressed in months. Statistical significance was assessed by the log-rank test
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chemotherapy for skeletal metastasis [HR (95% CI) 9.155
(4.584–18.284), p < 0.000], and orthopedic surgical treat-
ment for skeletal metastasis [HR (95% CI) 1.691 (1.142–
2.504), p = 0.005] (Fig. 3). In addition, the multivariate
analysis performed to determine which factors were an
independent prognostic factor revealed that age under
60 years at diagnosis [HR (95% CI) 1.549 (1.124–2.134),
p = 0.007], small cell lung cancer pathology type [HR
(95% CI) 2.045 (1.373–3.047), p < 0.000], chemotherapy
for skeletal metastasis [HR (95% CI) 7.121 (3.542–
14.317), p < 0.000], and orthopedic surgical treatment for
skeletal metastasis [HR (95% CI) 1.710 (1.148–2.547), p
Table 2 Univariate and multivariate regression analysis of lung cancer survival
Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age (< 60 vs. ≥ 60) 1.538 1.159–2.161 0.002 1.549 1.122–2.139 0.008
Sex (male vs. female) 1.086 0.790–1.492 0.595
Smoking (nonsmoker vs. smoker) 1.114 0.818–1.517 0.473
Pathology (NSCLC vs. SCLC) 1.630 1.114–2.385 0.008 1.711 1.157–2.532 0.007
EGFR (positive vs. negative) 1.462 0.769–2.780 0.225
Number of distant organ metastasis (only 1 vs. over 2) 1.177 0.812–1.705 0.367
Chemotherapy (yes vs. no) 9.827 4.939–19.552 0.000 8.064 3.981–16.332 0.000
Radiation therapy (yes vs. no) 1.597 1.048–2.434 0.021 1.791 1.170–2.742 0.007
Orthopedic surgery (yes vs. no) 1.377 0.931–2.036 0.092
Fig. 3 Kaplan-Meier plots of skeletal metastasis survival in a) age at diagnosis of lung cancer, b) pathologic type of lung cancer, c) whether
chemotherapy was performed for skeletal metastasis, and d) whether orthopedic surgery was performed for skeletal metastasis. Median survivals
are expressed in months. Statistical significance was assessed by the log-rank test
Cho et al. BMC Cancer          (2019) 19:303 Page 6 of 10
= 0.008] were significant independent prognostic factors
(Table 3).
Discussion
Majority (~ 50%) of lung cancer patients suffer from
bone metastases, mainly spine and rib involvement.
[13, 14]. In a cohort study of 112 patients with lung
cancer who had bone metastases, metastatic spinal cord
compression (MSCC) occurred in 31cases (27.7%). Pa-
tients with MSCC had a 6.1 times greater risk of devel-
oping MSCC and poor median survival (4.4 months) and
the medial survival time after the occurrence of MSCC
was 2.8 months [15]. Possible mechanism of spinal me-
tastasis is access to the vertebral bodies in the thoracic
and lumbar spine through the plexus vertebral system
and the high bone marrow flow of some skeletal ele-
ments [16, 17]. Spine metastasis of lung cancer has been
described in several papers, and survival has been rela-
tively well analyzed. Therefore, in this presented article,
we discuss pure appendicular skeletal metastasis of lung
cancer, except spine metastasis.
The presence of osteolytic lesions leads to weakeness
of bone tissue and leads to the emergence of SREs, in-
cluding hypercalcemia, pathologic fractures, and com-
pression fractures of the spine that might require
treatment [18]. Systemic therapies that block osteoclast
activity, including bisphosphonates (zoledronic acid) and
receptor activator for nuclear factor-κβ ligand (RANKL)
inhibitors (denosumab), is known to reduce the inci-
dence of SREs, but they have a modest impact on sur-
vival [10]. Denosumab demonstrated superior efficacy
than zoledronic acid in delaying the appearance of SREs
in NSCLC in a randomized trial; however, denosumab
showed no differences regarding osteonecrosis of the
jaw, a serious complication encountered in patients
treated long-term [19, 20].
Approximately two-thirds of all patients with lung
cancer have advanced disease at the time of diagnosis,
and these patients are known to have low long-term sur-
vival rates. Patients with a lung cancer survival of more
than 2 years are reclassified as belonging to the
long-term survival group. In long-term survival groups,
the survival period can be increased by using different
treatment modalities [21–24]. Long-term survivors ac-
count for 7.2–12.8% of all patients with advanced lung
cancer, and stage and performance status are significant
factors in these patients [24–27]. In general, the prog-
nostic factors in metastatic tumors of the skeletal system
are performance status, number of skeletal metastases,
pain level, and primary carcinoma; in patients with lung
cancer, breast cancer, and prostate cancer, these are dif-
ferent from each other [28–33]. In a previous study,
Sugiura et al. suggested prognostic factors, including
histologic diagnosis, skeletal metastasis location, and use
of EGFR-targeted agents, in the prognosis of 118 pa-
tients with lung cancer who had skeletal metastasis [13].
In this study, only 71 cases of EGFR mutation were
investigated, this is because it is a subject collected
from 2005 to 2015. EGFR mutation has been actively
investigated since 2011 in South Korea. We investi-
gated the patients with skeletal metastasis. Therefor
we do not have control, the patient without skeletal
metastasis, to compare whether the EGFR mutation is
a risk factor for developing skeletal metastasis. The
number of metastatic sites, timing of recurrence,
histologic adenocarcinoma, and treatment modality
for metastatic tumors are known to be significant
prognostic factors for recurrent lung cancer [34–36].
In this study, survival after the diagnosis of skeletal
metastasis is discussed, so the results are somewhat
different for the factors affecting survival rates.
In the treatment principles of pathologic fractures of
the long bones, bone dissemination can be grouped into
three categories: solitary lesion, oligometastases, or dif-
fuse. Solitary lesions can be treated with curative mea-
sures. Especially for patients with kidney and breast
Table 3 Univariate and multivariate regression analysis of skeletal metastasis survival
Variable Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age (< 60 vs. ≥ 60) 1.619 1.183–2.216 0.002 1.549 1.124–2.134 0.007
Sex (male vs. female) 1.157 0.843–1.587 0.338
Smoking (nonsmoker vs. smoker) 1.189 0.870–1.623 0.141
Pathology (NSCLC vs. SCLC) 1.950 1.309–2.904 0.000 2.045 1.373–3.047 0.000
EGFR (positive vs. negative) 1.479 0.772–2.833 0.208
Number of distant organ metastasis (only 1 vs. over 2) 1.058 0.722–1.550 0.247
Chemotherapy (yes vs. no) 9.155 4.584–18.284 0.000 7.121 3.542–14.317 0.000
Radiation therapy (yes vs. no) 1.291 0.840–1.982 0.059
Orthopedic surgery (yes vs. no) 1.691 1.142–2.504 0.005 1.710 1.148–2.547 0.008
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cancers, it is hypothesized that more aggressive local
treatment might improve survival in the case of oligo-
metastases [37]. However, skeletal metastasis from lung
cancer is generally treated palliatively. This tendency is
due to the fact that patients with lung cancer have more
frequent and more severe pulmonary dysfunction, affect-
ing their ability to tolerate general anesthesia for ortho-
pedic surgery. Moreover, the lifespan in patients with
lung cancer is not as long as that in patients with breast
or kidney cancers. If orthopedic surgery is planned, com-
prehensive anesthetic plan should be established includ-
ing laboratory studies and accurate lung function should
be evaluated using high-resolution CT and pulmonary
function. A surgical approach to skeletal metastasis is
possible if partial anesthesia, including nerve plexus
block, is appropriately used. The first step of treatment
strategy is to decide whether surgery is required, and
this should be determined in a multidisciplinary meet-
ing. Radiotherapy should be considered as standard
treatment for small lesions, whereas surgery is useful for
actual fractures and impending fractures. The purpose
of all treatments is to maintain optimal pain-free func-
tion of the extremities and direct weight bearing and
mobility. Based on prospective researches, axial cortical
involvement of > 30mm and circumferential cortical in-
volvement of > 50% is considered as risk factors for frac-
ture [38]. The next step is to decide the fixation types.
After orthopedic surgery, the expected lifetime and the
implant types are important issues. It is fortunate if the
implant survives until the patient dies. If the implant
wears out before the patient dies, additional
decision-making is necessary, including whether to
reoperate. The rigid fixation should be durable enough
to use during remaining lifetime of the patient, and re-
covery time should not exceed the life expectancy of the
fixation. The aim of our study is to provide the strategy
for lung cancer patient with skeletal metastasis. For the
patients expected survival is less than 6 weeks, the pos-
sible benefits of surgical intervention must be strongly
considered and conservative care should be sought. For
the cases need absolute requirement for surgical inter-
vention, minimally invasive surgery is needed with short
recovery time. For patients with an expected short-term
survival (between 6 weeks and 6months), more invasive
procedures are warranted. However, the use of extensive
reconstruction or large, complication-prone prostheses
should not be considered. For cases with long-term sur-
vivor who expected more than 6months needs compre-
hensive surgery [39]. Our findings revealed that there
was no statistically significant difference in survival after
the diagnosis of primary lung cancer between our pa-
tient groups. However, survival after diagnosis of skeletal
metastasis from lung cancer was significantly longer in
patients who underwent orthopedic surgery for skeletal
metastasis of lung cancer than in patients who did not
receive surgery for skeletal metastasis. Decisions about
whether to perform orthopedic surgery for skeletal me-
tastasis were made using the flowchart shown in Fig. 4.
Of the 161 patients who did not undergo orthopedic
surgery for skeletal metastasis, 9 (5.6%) survived less
than 6 weeks; 1 patient (2.4%) had undergone other sur-
gery but died in less than 6 weeks. It may not be possible
to exclude the possibility of selection bias from the
present study, but this is a limitation of prospective
Fig. 4 Decision-making diagram for skeletal metastasis in patients with lung cancer
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studies. However, it should be understood that this dif-
ference was not statistically significant, and we have
attempted to comply with standard procedures in
decision-making (Fig. 4).
Conclusion
In our study, we had good prognostic factor for longer
survival (less than 60 years old, chemotherapy as treat-
ment for skeletal metastasis, NSCLC rather than SCLC,
and underwent orthopedic surgery for skeletal metasta-
sis). Patients died sooner if they had skeletal metastasis
at the time of diagnosis of primary lung cancer. Patients
with skeletal metastasis from primary lung cancer should
be supported in developing a deeper understanding of
appropriate treatment to improve their survival and
quality of life.
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